Babesiosis, Tafenoquine Safety and Ongoing Clinical Studies

Lyme

About The Event

Join ILADS for an informative 1-hour webinar sponsored by 60 Degrees Pharmaceuticals, designed to provide a foundational understanding of babesiosis and Tafenoquine’s clinical development program in Babesiosis, a tick-borne parasitic infection, which poses a growing health concern in many regions.

This session will cover:

– Basics of Babesiosis: What it is, how it’s transmitted, symptoms, and diagnostic methods.
– Tafenoquine Treatment: An in-depth look at this innovative therapeutic option and overview of the 12 month safety trial for the approved indication of Malaria Prevention.
– Ongoing Clinical Studies: Insights into the latest research for the treatment of Babesiosis.

About The Host

Geoff Dow, PhD and CEO of 60 Degrees Pharma, this webinar will benefit patients, healthcare professionals, researchers, and anyone interested in expanding their knowledge about babesiosis and Tafenoquine.